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Abstract Angiotensin Π (All) plays a crucial role in controlling 
the proliferation and migration of vascular smooth muscle cells 
(VSMCs). The present study was undertaken to determine if 
troglitazone (Tro) has an effect on the G-protein coupled 
signaling through All type I (AT-1) receptors in cultured rat 
aortic VSMCs. All-induced MAP kinase activation was 
inhibited 67.9% by Tro. All-induced DNA synthesis and 
migration was completely inhibited by Tro or by the AT-1 
receptor blocker irbesartan. The present study demonstrates that 
troglitazone inhibits All-induced DNA synthesis, migration and 
MAP kinase activation in VSMCs which are important 
molecular events for the development of neointimal hyperplasia 
and atherosclerosis. 
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1. Introduction 
Intimal accumulation of vascular smooth muscle cells 
(VSMCs) is an important event in the development of both 
restenosis and atherosclerosis. The accumulation of VSMC in 
the intima results from both cell proliferation and directed 
migration of VSMCs from the media into the intima [1,2]. 
These processes are regulated by several growth factors which 
may be released by cells within the injured vessel or from 
circulating cells. We have recently shown that troglitazone 
(Tro), a member of the thiazolidinedione class of oral anti-
diabetic drugs, prevents VSMC proliferation and migration in 
the vitro and substantially attenuates neointimal hyperplasia 
in the injured rat aorta [3]. The mechanism of this effect ap-
pears to be through the inhibition of the MAP kinase path-
way which is activated in response to, and integrates signals 
from both, the basic fibroblast growth factor (bFGF) and 
platelet-derived growth factor (PDGF) tyrosine kinase recep-
tors. More specifically, we determined that Tro inhibited the 
nuclear actions of MAP kinase at a point downstream of 
MAP kinase activation by MAP kinase kinase (MEK) [3]. 
Angiotensin II is a peptide growth factor, generated in the 
vascular wall [4] which is involved in regulation of VSMC 
proliferation and migration, and, when elevated in the circu-
lation, significantly enhances neointimal hyperplasia [5,6]. In 
VSMC, most of these effects of All are mediated via the AT-1 
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receptor, which is a G-protein coupled receptor [7]. Activation 
of the AT-1 receptor leads to increased Ca2+ mobilization, 
activation of protein kinase C, increased inositol triphosphate 
formation, and activation of the RAS-RAF-MEK-MAP ki-
nase pathway [8]. We have recently reported that All and 
PDGF-induced VSMC migration requires MAP kinase acti-
vation [9]. In the present study, we investigated the effect of 
troglitazone on All mediated MAP kinase activation, migra-
tion and DNA synthesis in cultured rat aortic smooth muscle 
cells. 
2. Materials and methods 
2.1. Cell culture 
Rat aortic smooth muscle cells were prepared from thoracic aorta 
of 2-3-month-old Sprague-Dawley rats using the explant technique 
[10]. The cells were cultured in DMEM containing 10% FBS, 150 
mmol/1 HEPES, 100 U/ml penicillin, 100 μ^ητΐ streptomycin and 
200 mmol/1 glutamine (Sigma, St. Louis). The purity and identity of 
the smooth muscle cell cultures were verified by using a monoclonal 
antibody against smooth muscle oc-actin (Sigma). For all experiments, 
early passaged (4 or less) rat VSMCs were grown to 60-70% con-
fluency and made quiescent by serum starvation for at least 16 h, 
when MAP kinase activity was assayed. For all data shown, each 
individual experiment represented in the n value was performed using 
an independent preparation of VSMCs. 
2.2. MAP in-gel kinase assay 
MAP kinase activity was measured by the in gel kinase assay as 
described [3]. Troglitazone was given 30 min before inducing MAP 
kinase activation with All for 10 min. For the data shown, each 
individual experiment represented in the n value was performed using 
an independent preparation of VSMCs. Densitometric analysis was 
performed using NIH Image 1.60 software on a Macintosh PC. 
2.3. VSMC DNA synthesis 
Incorporation of the thymidine analogue, bromodeoxyuridine 
(BrdU), was measured to determine the effect of All on DNA synth-
esis as described previously [11]. VSMC were plated out at 3.0 X104 
cells on 24-well plates (Falcon primaria) in DMEM with 10% FBS for 
48 h. After serum starvation for 36 h in DMEM/0.2% FBS, incuba-
tion with All (1 μΜ, Bachern, Torrance, CA), irbesartan (100 μΜ), 
and Tro (1, 10 or 20 μΜ) was performed for the next 20 h. Troglita-
zone was a generous gift from Parke-Davis, Ann Arbor. The AT-1 
receptor blocker irbesartan was kindly provided by Bristol Myers 
Squibb (Princeton, NJ). Then 15 μΜ BrdU (Sigma) was added, and 
the incubation was continued for another 4 h. After several washes 
with PBS, cells were fixed, permeabilized with 1 N HC1 and stained 
with an anti-BrdU monoclonal antibody (Zymed, San Francisco, CA) 
using the ABC method. A fast red substrate system (Dako Corp., 
Capinteria, CA) was used as a chromagen; counterstaining was per-
formed with hematoxylin. Cell nuclei with BrdU incorporation ap-
peared red and were counted in 4-6 different high power fields/well 
and related to total cell number/high power field. 
2.4. Migration 
Chemotaxis experiments were performed as described in [3]. VSMC 
migration was examined in transwell cell culture chambers (Costar, 
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Cambridge, MA) using a gelatin-coated polycarbonate membrane 
with 8 urn pores. The number of VSMCs per 320 X high power field 
(HPF) that migrated to the lower surface of the filters was determined 
microscopically. 4-6 randomly chosen HPFs (magnification X320) 
were counted per filter. Experiments were performed in duplicate or 
triplicate, and were repeated at least three times. 
2.5. Statistical analysis 
Analysis of variance, paired or unpaired i-test, was performed for 
statistical analysis, as appropriate. P values less than 0.05% were 
considered to be statistically significant. Data are expressed as 
mean±S.E.M. 
3. Results 
3.1. Troglitazone inhibits MAP kinase activation by All 
Rat aortic VSMCs were made quiescent by 16 h treatment 
in serum-free culture medium. Quiescent VSMCs exhibited 
low MAP kinase activity, as demonstrated by the faint signals 
produced by the phosphorylation of myelin basic protein by 
p44 (ERK1) and p42 (ERK2) in the in-gel kinase assay (Fig. 
1A, lane 1). Strong induction of ERK1 and ERK2 («5-fold) 
activity was observed after 10 min treatment with All (Fig. 
la,b). All-induced MAP kinase activation was inhibited in a 
concentration-dependent manner by Tro (Fig. la). At 20 μΜ 
Tro inhibited the All-induced activation of ERK1 and ERK2 
by 67.9% in VSMCs (« = 4, p<0 .01 vs. All alone). 
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Fig. 1. All (1 μΜ) induces phosphorylation of ERK1 and ERK2 in 
quiescent rat VSMC, which is inhibited by increasing concentrations 
of Tro (1-20 μΜ). Cells were starved for at least 16 h in serum-free 
DMEM and stimulated with All for 10 min. MAP kinase activity 
was measured by in-gel kinase assay, which demonstrates phosphor-
ylation at 42 and 44 kDa size, bands specific for ERK1 and ERK2. 
(a) Representative autoradiography of MAP kinase activity induced 
by All in the absence and presence of Tro (1-20 μΜ). (b) Results 
of the densitometric analysis of 4 different experiments. MAP kinase 
activity induced by All is set as 100% (*/? < 0.01 vs. control, 
V<0.05 vs. All alone, /><0.01 vs All alone; n = 4, mean± 
S.E.M.). 
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Fig. 2. DNA synthesis was measured by incorporation of bromo-
deoxyuridine (BrdU) and visual quantification of 4-6 high power 
fields (HPF)/well. Experiments were performed in duplicates. Quies-
cent VSMCs were stimulated with All in the presence or absence of 
troglitazone (Tro 1-20 μΜ) or the AT-1 receptor blocker irbesartan 
(Irb 100 μΜ) for 20 h before addition of BrdU. All induced DNA 
synthesis was inhibited by Tro in a concentration-dependent fashion 
and was also prevented by losartan. Tro (20 μΜ) or Irb alone did 
not affect DNA synthesis compared to unstimulated cells (*/;<0.01 
vs. control, */> < 0.04 vs All, '/> < 0.01 vs. All alone, n = 12). 
3.2. Troglitazone inhibits All mediated DNA synthesis in rat 
VSMC 
DNA synthesis was determined by incorporation of bromo-
deoxyuridine (BrdU). All (1 μΜ) induced a 4-fold increase in 
DNA synthesis (from 4.4± 1.1 control to 18.2±2.2% positive 
cells, p<0.0l, n = 8), which was completely inhibited by the 
AT-1 receptor blocker irbesartan (100 μΜ, /> < 0.01 vs. All 
alone). Tro (1-20 μΜ) demonstrated a concentration-depend-
ent inhibition of All-induced DNA synthesis (Fig. 2). The 
maximal concentration of Tro (20 μΜ) completely inhibited 
the effect of All on DNA synthesis (p<0.01 vs. All alone). 
3.3. Troglitazone inhibits All mediated migration in rat VSMC 
VSMC migration induced by All was increased more than 
3-fold (n = 8, p < 0.01) as compared to unstimulated cells. Pre-
treatment with various concentrations of Tro resulted in a 
significant inhibition at 1 μΜ Tro (79%, p<0.01) of the 
All-induced effect with complete inhibition observed at 10 
and 20 μΜ Tro (p<0.01, Fig. 3). The AT-1 receptor blocker 
irbesartan significantly inhibited the All-induced migration 
(p<0.0l), whereas the AT-2 receptor blocker PD 123319 
(100 μΜ, Parke-Davis, Ann Arbor, MI) did not interfere 
with the migration towards All (Fig. 3). 
4. Discussion 
We have recently demonstrated that Tro attenuates neoin-
timal hyperplasia in the balloon injured rat aorta by inhibiting 
PDGF and bFGF actions on VSMC [3]. In in vitro experi-
ments Tro inhibited PDGF-mediated migration and bFGF-
induced VSMC proliferation. These effects may have resulted 
from Tro's ability to block the MAP kinase pathway at a 
point downstream of MAP kinase activation by MEK result-
ing in inhibition of two nuclear endpoints: (1) induction of c-
fos and (2) transactivation of serum response elements by the 
MAP kinase regulated transcription factor ELK1, which also 
activates c-fos [3]. In the present study, Tro also prevented 
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Fig. 3. Migration of rat aortic VSMC towards All was inhibited by 
troglitazone (Tro) in a concentration-dependent manner. All (1 μΜ) 
induced a significant increase in migrated cells, which was inhibited 
by Tro and by Irb (100 μΜ). Treatment with Tro or Irb alone in 
unstimulated cells did not affect baseline values. The AT-2 receptor 
antagonist PD123319 (PD123, 100 μΜ) did not inhibit the All-in-
duced migration (n = 8-16, mean±S.E.M., *p<0.0l vs. baseline, 
*;?<0.01 vs All alone). 
through MAP kinase that is initiated by either tyrosine kinase 
growth factor receptors [3] or a G-protein coupled, seven 
transmembrane domain receptor. Activation of MAP kinase, 
in turn, is required for both VSMC growth and migration. 
These results underscore the potential clinical efficacy of tro-
glitazone for prevention of both human restenosis and ather-
osclerosis. Troglitazone has already proved beneficial in im-
proving insulin resistance and reducing hyperinsulinemia in 
initial clinical trials involving obese subjects and patients 
with non-insulin dependent diabetes mellitus [17,20]. Future 
investigation will likely reveal whether troglitazone is also 
beneficial for vascular diseases. 
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